Summary of GlaxoSmithKline plc (LON:GSK) Ratings

"Buy" rating has 7, "Sell" are 1, while 9 are "Hold". Two Sigma Investments LP now owns 2,388,168 shares of the pharmaceutical company's stock valued at $84,708,000 after purchasing an additional 457,276 shares during the last quarter. The firm has a market cap of $98,879.84, a PE ratio of 13.89, a price-to-earnings-growth ratio of 2.12 and a beta of 0.84.

Shares of GSK stock traded down GBX 3.40 ($0.05) on Thursday, reaching GBX 1,394 ($19.26). About 2.92M shares traded. GlaxoSmithKline plc (NYSE:GSK) has declined 10.07% since April 22, 2017 and is downtrending. The stock underperformed the S&P 500 by 11.55%.

Buckhead Capital Management Llc increased its stake in Pepsico Inc (PEP) by 12.25% based on its latest 2017Q4 regulatory filing with the SEC. The Beutel Goodman & Co Ltd holds 5.89 million shares with $249.13 million value, up from 5.54M last quarter. It closed at $0.76 lastly. It is down 30.54% since April 20, 2017 and is uptrending. It has outperformed by 70.65% the S&P500. (LON:GSK) has 54 ratings reports on April 22, 2018 according to StockzIntelligence.

GlaxoSmithKline PLC (LON:GSK) has had their stock rating maintained as a solid Neutral by professional analysts at JP Morgan Cazenove. They expect $0.72 earnings per share, up 16.13% or $0.10 from last year's $0.62 per share.

Total analysts of 6 have positions in GlaxoSmithKline (NYSE:GSK) as follows: 4 rated it a "Buy", 0 with "Sell" and 2 with "Hold". Therefore 36% are positive. GlaxoSmithKline plc disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Former 10% Owner Glaxosmithkline Plc has sold 503,150 shares of GlaxoSmithKline plc (GSK) in trading session dated February 23, 2015. The firm has "Neutral" rating by JP Morgan given on Wednesday, December 13.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings results on Wednesday, February 7th. JPMorgan Chase reissued a "neutral" rating on shares of GlaxoSmithKline in a report on Thursday, January 11th. BNP Paribas upgraded the shares of GSK in report on Tuesday, September 15 to "Neutral" rating. On Thursday, February 8 the firm earned "Hold" rating by Shore Capital. UBS set a GBX 1,600 ($22.91) price target on GlaxoSmithKline and gave the stock a "buy" rating in a research report on Thursday, April 5th. The company was maintained on Friday, October 27 by Barclays Capital. Class A (NYSE:DATA). (NYSE:GSK) has 67% bullish analysts. Therefore 63% are positive. Air Products & Chemicals had 60 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of Micron Technology, Inc. The rating was maintained by Argus Research on Friday, August 12 with "Buy". The firm has "Sector Weight" rating by Pacific Crest given on Friday, November 18. The company had revenue of $10.14 billion during the quarter, compared to analysts' expectations of $9.89 billion. Deutsche Bank maintained GlaxoSmithKline plc (LON:GSK) on Wednesday, March 28 with "Hold" rating. On Monday, July 11 the stock rating was upgraded by Seaport Global to "Buy". The stock of GlaxoSmithKline plc (LON:GSK) has "Hold" rating given on Friday, March 23 by Deutsche Bank. Suntrust Robinson initiated Q2 Holdings, Inc. (NYSE:WWW) earned "Sell" rating by Susquehanna on Thursday, June 1.

Investors sentiment decreased to 1.24 in 2017 Q4. Its up 0.14, from 0.88 in 2017Q3.

The stock decreased 0.95% or $0.51 during the last trading session, reaching $52.96. Jones Companies Lllp stated it has 78,517 shares. Fred Alger Management Incorporated holds 0.02% or 136,320 shares in its portfolio. (NYSE:QTWO). Driehaus Cap Management Ltd owns 0.25% invested in Q2 Holdings, Inc. (NYSE:VZ) for 3,801 shares. Colony Gru Limited holds 1.27% or 169,461 shares in its portfolio. 845,945 were accumulated by Federated Inc Pa. Linscomb Williams Incorporated owns 103,968 shares for 0.45% of their portfolio. Schroder Invest Management invested in 0.14% or 694,739 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Related Articles